Company description

Atara Biotherapeutics (ticker symbol ATRA) is a leading clinical-stage biopharmaceutical company that is dedicated to developing transformative therapies for patients suffering from serious medical conditions. Founded in 2012, Atara focuses on developing allogeneic or off-the-shelf T-cell immunotherapies, which harness the power of the immune system to fight disease. Their innovative treatments target a range of rare and debilitating diseases, including autoimmune disorders, viral infections, and cancer. The company's pipeline includes several promising candidates, such as ATA188 for the treatment of multiple sclerosis and ATA2271 for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. With a team of experienced scientists and a commitment to advancing the field of immunology, Atara Biotherapeutics is poised to revolutionize the way we treat devastating diseases.